Compass Therapeutics, Inc.

Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based oncology therapeutics. The company's pipeline centers on bispecific and monoclonal antibody candidates designed to target multiple pathways simultaneously. Its lead program, tovecimig, is a bispecific antibody blocking Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) to inhibit tumor angiogenesis. Additional candidates include CTX-471, an IgG4 monoclonal antibody agonist of the CD137 co-stimulatory receptor; CTX-8371, a bispecific targeting PD-1 and PD-L1 checkpoint proteins; and CTX-10726, a bispecific combining PD-1 and VEGF-A inhibition.

The company operates as a pre-revenue clinical-stage entity with no established revenue streams. Compass maintains operations in Boston, Massachusetts, with a workforce of approximately 35 full-time employees. The company was incorporated in Delaware and is publicly listed on Nasdaq. Founded in 2014, Compass remains in the development phase, with its therapeutics currently advancing through clinical evaluation.